ArticleCancer research2014
Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma.
Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- SIRT2 is associated with prognosis, ferroptosis susceptibility, and immune infiltration in lung adenocarcinoma.Frontiers in oncology · 2026Article
- Intratumor Heterogeneity Predicts Prognosis in Lepidic Predominant Lung Adenocarcinoma.Thoracic cancer · 2025Article
- Integrating machine learning and single-cell analysis to uncover lung adenocarcinoma progression and prognostic biomarkers.Journal of cellular and molecular medicine · 2024Article
- Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinoma.Cell reports. Medicine · 2024Article
- Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.Cancer medicine · 2023Article
- Gene expression profiling using targeted RNA-sequencing to elucidate the progression from histologically normal lung tissues to non-invasive lesions in invasive lung adenocarcinoma.Virchows Archiv : an international journal of pathology · 2022Article
- Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.Frontiers in immunology · 2022Article
- Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.BMC cancer · 2021Article
- Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts.Molecular & cellular proteomics : MCP · 2021Article
- Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.Mayo Clinic proceedings · 2020Article
- Genomic and immune profiling of pre-invasive lung adenocarcinoma.Nature communications · 2019Article
- In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth-a clinically relevant distinction.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.Thoracic cancer · 2019Article
- Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing.Scientific reports · 2019Article
- Germline Predisposition and Copy Number Alteration in Pre-stage Lung Adenocarcinomas Presenting as Ground-Glass Nodules.Frontiers in oncology · 2019Article
- Multifocal adenocarcinoma: perspectives, assumptions and elephants.Journal of thoracic disease · 2018Article
- Genomic rearrangements in sporadic lymphangioleiomyomatosis: an evolving genetic story.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.Cancer research · 2016Article
- Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The development of adenocarcinoma of the lung is believed to proceed from in situ disease (adenocarcinoma in situ, AIS) to minimally invasive disease with prominent lepidic growth (minimally invasive adenocarcinoma, MIA), then to fully invasive adenocarcinoma (AD), but direct evidence for this model has been lacking. Because some lung adenocarcinomas show prominent lepidic growth (AD-L), we designed a study to address the lineage relationship between the lepidic (noninvasive) component (L) and the adjacent nonlepidic growth component representing invasive disease within individual tumors. Lineage relationships were evaluated by next-generation DNA sequencing to define large genomic rearrangements in microdissected tissue specimens collected by laser capture. We found a strong lineage relationship between the majority of adjacent lepidic and invasive components, supporting a putative AIS-AD transition. Notably, many rearrangements were detected in the less aggressive lepidic component, although the invasive component exhibited an overall higher rate of genomic rearrangement. Furthermore, a significant number of genomic rearrangements were present in histologically normal lung adjacent to tumor, but not in host germline DNA, suggesting field defects restricted to zonal regions near a tumor. Our results offer a perspective on the genetic pathogenesis underlying adenocarcinoma development and its clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.